GSK-Partnered Alector Hit By Renewed Dementia Skepticism

Doubts About Biomarker

Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker  neurofilament light chain.

Brain research
New investment is flooding into neuroscience, but understanding of disease mechanisms still lags far behind areas such as oncology and cardiovascular disease

Alector a biotech firm focused on neurodegeneration that recently signed a collaboration with GlaxoSmithKline worth up to $2.2bn, has seen its share price sink despite unveiling promising results from its lead candidate.

That reflects a broader retrenchment in neuroscience biotech stocks, which have benefitted hugely from Biogen’s Aduhelm (aducanumab) approval in June,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip